In vivo experiments further corroborated these findings, where RGX202 treatment in subcutaneous tumor‐bearing mice, co‐injected with CT26 and NIH3T3 (LV‐VEC and LV‐VTN) cells, led to a significant reduction in tumor volume and weight compared to control groups (Figure 6E–G). Here, DDX53 is linked to neoplasm.